This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Chiesi Farmaceutici S.p.A.
Drug Names(s): AR-C69931, AR-C69931MX, Cangrelor, Kengrexal (EU)
Description: Cangrelor is a short-acting, parenteral, anti-platelet compound that, like oral ticlopidine and oral clopidogrel, antagonizes platelets’ P2Y12 receptor in order to achieve its antithrombotic effects.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
In December 2003, The Medicines Company announced that it had acquired, from AstraZeneca, the rights to develop cangrelor. The Medicines Company will develop, market, and sell cangrelor worldwide excluding Japan, China, Korea, Taiwan, and Thailand. AstraZeneca will receive royalties on sales in these areas as well as milestone payments.
In June 2010, The Medicines Company entered into an amendment to its License Agreement with AstraZeneca. The Amendment requires the Company to commence certain clinical studies of cangrelor specified in the Amendment and to use commercially reasonable efforts to file new drug applications for cangrelor, eliminating the specific time lines previously specified in the License Agreement. Additionally, the Amendment terminates certain regulatory assistance obligations of AstraZeneca, provides AstraZeneca with an option to obtain certain commercial support services, to be confirmed, from the...See full deal structure in Biomedtracker
Partners: AstraZeneca PLC
Additional information available to subscribers only: